NGEN

NervGen Pharma Corp. Common stock (NGEN) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Negative ROIC indicates capital deployment is still below peer norms, but the near-zero debt-to-equity ratio limits balance-sheet drag versus more levered competitors.

A current ratio above 1.1 suggests short-term liquidity is adequate, which is structurally better than peers with tighter working-capital buffers.

Cash conversion cycle reported at zero implies working-capital discipline or limited inventory intensity, supporting operational flexibility relative to peers with longer cycles.

Weaknesses

Score:

ROIC of -7.2% shows the business is destroying value on invested capital, leaving it structurally weaker than profitable peers with positive returns.

Net debt to EBITDA of 0.88x still adds financial burden versus net-cash peers, constraining resilience if margins or demand weaken.

Liquidity is only modestly above 1.0x, so the company has less cushion than stronger peers with materially higher current and quick ratios.

Opportunities

Score:

If management lifts ROIC toward peer-positive levels, the company can narrow the valuation and operating gap versus better-capitalized competitors.

Low leverage provides room to fund growth or restructuring more flexibly than indebted peers, improving strategic optionality over the next 2–5 years.

Working-capital efficiency can translate into faster cash generation than peers if revenue scales without proportional balance-sheet expansion.

Threats

Score:

Persistent negative ROIC threatens long-term competitiveness because peers with positive capital returns can reinvest faster and widen their structural advantage.

Moderate leverage leaves less downside protection than net-cash peers, increasing vulnerability if earnings volatility raises refinancing or covenant pressure.

Without evidence of durable margin or growth momentum, the company risks lagging peers that compound value through stronger operating leverage.

Overall Score

Score:

NGEN’s structural positioning is weak versus peers because negative capital returns outweigh modest liquidity and low leverage advantages.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on NervGen Pharma Corp. Common stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →